Genmab — Februar 2018
-
det er da et tal, der gør, at Genmab i mine øjne ikke guider under 2 milliarder dollars i aften
-
87,8 i december.
-
ROW bliver vel væsentligt bedre end 600mio med Nice, Japan og første linje
-
Det er stagnation så det batter for et nylanceret produkt i mine øjne - og vel at mærke stagnation, hvor vi ligger meget langt fra peaksale - ingen tvivl om at 1 linie vil give en del - men pt kan jeg på ingen måde se at vi når 8 milliarder dollars i peaksale i MM - med mindre der kommer en fornuftig forklaring
-
Sukkeralf..Stil endelig spørgsmålene på Q&A.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind